Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/annrheumdis-2020-218122 http://scihub22266oqcxt.onion/10.1136/annrheumdis-2020-218122 32620597!7509526!32620597     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Rheum+Dis 2020 ; 79 (10): 1277-1285 Nephropedia Template TP {{tp|p=32620597|t=2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study |pdf=|usr=}}{{32620597}} gab.com Text Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study JO: Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=32620597 #FOAvip OBJECTIVES: To assess the safety and efficacy of interleukin (IL)-6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation. METHODS: We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO(2)/FiO(2) <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels). Sarilumab 400 mg was administered intravenously in addition to standard of care and results were compared with contemporary matched patients treated with standard of care alone. Clinical improvement, mortality, safety and predictors of response were assessed at 28 days. RESULTS: Twenty-eight patients were treated with sarilumab and 28 contemporary patients receiving standard of care alone were used as controls. At day 28 of follow-up, 61% of patients treated with sarilumab experienced clinical improvement and 7% died. These findings were not significantly different from the comparison group (clinical improvement 64%, mortality 18%; p=NS). Baseline PaO(2)/FiO(2) ratio >100 mm Hg and lung consolidation <17% at CT scan predicted clinical improvement in patients treated with sarilumab. Median time to clinical improvement in patients with lung consolidation <17% was shorter after sarilumab (10 days) than after standard treatment (24 days; p=0.01). The rate of infection and pulmonary thrombosis was similar between the two groups. CONCLUSIONS: At day 28, overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard of care. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline. Twit Text FOAVip Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study ????Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=32620597 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32620597 #FOAvip English Wikipedia <ref>{{Cite pmid|32620597}}</ref> Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study #MMPMID32620597 Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L Ann Rheum Dis 2020[Oct]; 79 (10): 1277-1285 PMID32620597show ga OBJECTIVES: To assess the safety and efficacy of interleukin (IL)-6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation. METHODS: We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO(2)/FiO(2) <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels). Sarilumab 400 mg was administered intravenously in addition to standard of care and results were compared with contemporary matched patients treated with standard of care alone. Clinical improvement, mortality, safety and predictors of response were assessed at 28 days. RESULTS: Twenty-eight patients were treated with sarilumab and 28 contemporary patients receiving standard of care alone were used as controls. At day 28 of follow-up, 61% of patients treated with sarilumab experienced clinical improvement and 7% died. These findings were not significantly different from the comparison group (clinical improvement 64%, mortality 18%; p=NS). Baseline PaO(2)/FiO(2) ratio >100 mm Hg and lung consolidation <17% at CT scan predicted clinical improvement in patients treated with sarilumab. Median time to clinical improvement in patients with lung consolidation <17% was shorter after sarilumab (10 days) than after standard treatment (24 days; p=0.01). The rate of infection and pulmonary thrombosis was similar between the two groups. CONCLUSIONS: At day 28, overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard of care. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline. |Administration, Intravenous[MESH] |Anti-Bacterial Agents/therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |Bacteremia/epidemiology[MESH] |Betacoronavirus[MESH] |C-Reactive Protein/*immunology[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Cohort Studies[MESH] |Coinfection/epidemiology[MESH] |Coronavirus Infections/diagnostic imaging/*drug therapy/immunology/mortality[MESH] |Drug Combinations[MESH] |Enzyme Inhibitors/therapeutic use[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Inflammation/*immunology[MESH] |Interleukin-6/*immunology[MESH] |Italy[MESH] |Lopinavir/therapeutic use[MESH] |Lung/diagnostic imaging[MESH] |Male[MESH] |Middle Aged[MESH] |Noninvasive Ventilation[MESH] |Oxygen Inhalation Therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnostic imaging/*drug therapy/immunology/mortality[MESH] |Proportional Hazards Models[MESH] |Receptors, Interleukin-6/antagonists & inhibitors[MESH] |Ritonavir/therapeutic use[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Time Factors[MESH] |Tomography, X-Ray Computed[MESH]Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia wit(epmc).pdf DeepDyve Pubget Overpricing